About DiaMedica

About Us

DiaMedica Therapeutics is a clinical-stage biopharmaceutical company committed to changing the treatment paradigm for acute ischemic stroke (AIS) and preeclampsia (PE). Our initial product candidate, DM199, mimics the behavior of naturally-occurring human tissue kallikrein-1 (KLK1) proteins to increase collateral circulation in stroke-affected tissue and improve blood pressure control and overall endothelial health.

Restoring Healthy Function to Multiple Body Systems

We believe that DM199 (rhKLK1) has the potential to treat multiple diseases. By restoring levels of the naturally occurring protein KLK1, DM199 therapy has the potential to improve circulation and overall function of critical systems, as well as reduce inflammation and oxidative stress. Our research is focused on exploring this potential in acute ischemic stroke, preeclampsia and other diseases where promoting homeostasis and improving blood flow throughout the body is beneficial.

Positioned for Success


We have developed a pharmacologically active recombinant form of KLK1. DM199 (rhKLK1) represents an optimized, patent-protected formulation combining closely related isoforms with varying degrees of glycosylation, a critical component of the candidate's effectiveness.


We have licensed a proprietary cell line technology that efficiently and reliably produces large amounts of KLK1. The patent-protected manufacturing process covers all the vectors and reagents used to manufacture DM199 at scale.


Our composition of matter and delivery patents are protected until 2033. Worldwide dose, route of delivery, formulation and indication patents provide coverage to 2038.

Replenishing An Essential Protein

DiaMedica Therapeutics is developing DM199, a recombinant protein replacement therapy intended to restore normal, healthy levels of a protein known as human tissue kallikrein-1 (KLK1). KLK1 is a naturally-occurring protein believed to stimulate the production of nitric oxide, prostacyclin, and endothelium-derived hyperpolarizing factors - critical local hormones that work synergistically to improve blood flow and reduce inflammation. We believe that DM199 has the potential to treat several vascular diseases.

Show Me How

One Treatment, Multiple Diseases

Our lead asset, DM199 (rhKLK1), is being tested as a treatment for neurological conditions and preeclampsia by boosting the body's production of KLK1.

See the Potential

Clinical Trials: a Team Effort

At DiaMedica Therapeutics, we work together with physician investigators and trial participants to demonstrate how potential new therapies can improve treatment options.

Join Our Effort

Leaders with Multinational Experience

Our leadership team draws on expertise in all stages of clinical and biopharmaceutical development.

Join Our Team

We are looking for individuals who are passionate about medicine to join our company.

View Job Openings

Get In Touch with Us

Reach out to us if you have any questions about our pipeline or clinical trials.

Contact Us